Administration of lymphodepletion chemotherapy followed by CD19-specific chimeric
antigen receptor (CAR)–modified T cells is a remarkably effective approach to treating …

The prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic
transplantation is dismal when treated with conventional approaches. While single‐target …

Relapsed and chemotherapy-refractory B-cell acute lymphoblastic leukemia (B-ALL) remain
significant causes of cancer-associated morbidity and mortality for children and adults …

Introduction: Advances in chimeric antigen receptor (CAR) T cell therapy have yielded
complete remission (CR) rates in relapsed/refractory B-ALL (rrB-ALL) of 70-95%. However …

Immunotherapy has demonstrated significant potential for the treatment of patients with
chemotherapy-resistant hematologic malignancies and solid tumors. One type of …

Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in
treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients …

Background CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of
initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) …

Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with
relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a …

Refractory or relapsed B lymphoblastic leukemia (B-ALL) patients have a dismal outcome
with current therapy. We treated 42 primary refractory/hematological relapsed (R/R) and 9 …

Purpose T cells can be genetically modified to express an anti-CD19 chimeric antigen
receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 …